Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WOBSE
ADC Name
DAN-222
Synonyms
DAN 222; DAN-222; DAN222
   Click to Show/Hide
Organization
Dantari
Drug Status
Phase 1
Indication
In total 1 Indication(s)
HER2(-) breast cancer [ICD11:2C60-2C65]
Phase 1
Drug-to-Antibody Ratio
60
Antibody Name
Undisclosed
Antigen Name
Undisclosed
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05261269
Phase 1
A dose-escalation study of the safety and pharmacology of dan-222 in subjects with metastatic breast cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Metastatic breast cancer.
Administration Dosage
1.00 mg/kg.
Related Clinical Trial
NCT Number NCT05261269  Clinical Status Phase 1
Clinical Description A dose-escalation study of the safety and pharmacology of dan-222 in subjects with metastatic breast cancer.
References
Ref 1 Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. Ann. Oncol. 2021 Sept; 32(5):Supplement S450.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.